Reviving a Discontinued Drug
When drugs are taken off the market because of concerns about their safety, it makes headlines. To access DrugPatentWatch’s list […]
When drugs are taken off the market because of concerns about their safety, it makes headlines. To access DrugPatentWatch’s list […]
Here’s a copy of the recent talk on Finding and Evaluating Branded and Generic Market Entry Opportunities. It’s based on
Finding and Evaluating Branded and Generic Market Entry Opportunities Read Post »
You would be surprised to find out just how many questions are answered by the analysis of the relationship that
Introduction Valuing pharmaceutical companies is a complex yet crucial task for investors, analysts, and stakeholders. The unique nature of the
Valuation of Pharma Companies: 5 Key Considerations Read Post »
Amid public outcry over rising costs of brand-name drugs, the prices of generic medicines have been falling, raising fears about
This paper was originally published by Melek Simsek, Berrie Meijer, Adriaan A.van Bodegraven, Nanne K.H. de Boer, and Chris J.J.
When referring to “big data” in the context of the drug industry, one should essentially think of a collection of
Generic drugs perform better financially if they get to market first. The advantage is amplified if they get there more than one month ahead of competitors.
Loss of exclusivity doesn’t mean the end of the income stream for branded drugs. Here’s how drug companies can mitigate the effects of drug patent expiration.
6 Ways to Maximize Product Value as Loss of Exclusivity Approaches Read Post »
Get fresh news and insights, drug patent expirations & more…